BioLargo, Inc.
BLGO · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $17,779 | $12,230 | $5,884 | $2,531 |
| % Growth | 45.4% | 107.9% | 132.5% | – |
| Cost of Goods Sold | $9,926 | $6,076 | $3,027 | $1,428 |
| Gross Profit | $7,853 | $6,154 | $2,857 | $1,103 |
| % Margin | 44.2% | 50.3% | 48.6% | 43.6% |
| R&D Expenses | $2,882 | $2,282 | $1,319 | $1,367 |
| G&A Expenses | $8,808 | $0 | $0 | $0 |
| SG&A Expenses | $9,302 | $8,058 | $6,731 | $6,172 |
| Sales & Mktg Exp. | $494 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $394 | -$74 | -$55 |
| Operating Expenses | $12,184 | $10,340 | $7,976 | $7,484 |
| Operating Income | -$4,331 | -$4,186 | -$5,119 | -$6,381 |
| % Margin | -24.4% | -34.2% | -87% | -252.1% |
| Other Income/Exp. Net | $1,929 | -$68 | $61 | -$458 |
| Pre-Tax Income | -$2,402 | -$4,635 | -$5,132 | -$6,894 |
| Tax Expense | $1,945 | $13 | $0 | $0 |
| Net Income | -$2,402 | -$3,504 | -$4,496 | -$7,377 |
| % Margin | -13.5% | -28.7% | -76.4% | -291.5% |
| EPS | -0.008 | -0.012 | -0.017 | -0.03 |
| % Growth | 34.1% | 26.8% | 43.6% | – |
| EPS Diluted | -0.008 | -0.012 | -0.017 | -0.03 |
| Weighted Avg Shares Out | 298,122 | 285,957 | 268,302 | 247,204 |
| Weighted Avg Shares Out Dil | 298,122 | 285,957 | 268,302 | 247,204 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $139 | $91 | $53 | $234 |
| Depreciation & Amortization | $255 | $0 | $45 | $20 |
| EBITDA | -$4,059 | -$4,186 | -$5,097 | -$6,703 |
| % Margin | -22.8% | -34.2% | -86.6% | -264.8% |